Inferring protein expression changes from mRNA in Alzheimer’s dementia using deep neural networks

Shinya Tasaki (), Jishu Xu, Denis R. Avey, Lynnaun Johnson, Vladislav A. Petyuk, Robert J. Dawe, David A. Bennett, Yanling Wang and Chris Gaiteri
Additional contact information
Shinya Tasaki: Rush University Medical Center
Jishu Xu: Rush University Medical Center
Denis R. Avey: Rush University Medical Center
Lynnaun Johnson: Rush University Medical Center
Vladislav A. Petyuk: Pacific Northwest National Laboratory
Robert J. Dawe: Rush University Medical Center
David A. Bennett: Rush University Medical Center
Yanling Wang: Rush University Medical Center
Chris Gaiteri: Rush University Medical Center

Nature Communications, 2022, vol. 13, issue 1, 1-15

Abstract: Abstract Identifying the molecular systems and proteins that modify the progression of Alzheimer’s disease and related dementias (ADRD) is central to drug target selection. However, discordance between mRNA and protein abundance, and the scarcity of proteomic data, has limited our ability to advance candidate targets that are mainly based on gene expression. Therefore, by using a deep neural network that predicts protein abundance from mRNA expression, here we attempt to track the early protein drivers of ADRD. Specifically, by applying the clei2block deep learning model to 1192 brain RNA-seq samples, we identify protein modules and disease-associated expression changes that were not directly observed at the mRNA level. Moreover, pseudo-temporal trajectory inference based on the predicted proteome became more closely correlated with cognitive decline and hippocampal atrophy compared to RNA-based trajectories. This suggests that the predicted changes in protein expression could provide a better molecular representation of ADRD progression. Furthermore, overlaying clinical traits on protein pseudotime trajectory identifies protein modules altered before cognitive impairment. These results demonstrate how our method can be used to identify potential early protein drivers and possible drug targets for treating and/or preventing ADRD.

Date: 2022
References: View references in EconPapers View complete reference list from CitEc
Citations: View citations in EconPapers (1)

Downloads: (external link)
https://www.nature.com/articles/s41467-022-28280-1 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:13:y:2022:i:1:d:10.1038_s41467-022-28280-1

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-022-28280-1

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().